These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15617645)

  • 41. Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors.
    Palmer CR; Brown MJ; Mancia G; Ruilope LM;
    JAMA; 2003 Apr 23-30; 289(16):2066-7; author reply 2069-70. PubMed ID: 12709455
    [No Abstract]   [Full Text] [Related]  

  • 42. Hypertension and cardiovascular risk reduction in African Americans: a roundtable discussion.
    J Natl Med Assoc; 2002 Nov; 94(11 Suppl):3S-36S. PubMed ID: 12443008
    [No Abstract]   [Full Text] [Related]  

  • 43. Age and sex do not bias the use of angiotensin-converting enzyme inhibitors in acute myocardial infarction and congestive heart failure.
    Blackman IC; Bond M; Bowling A; Banning A; Dudley N; Elder A; Martin A; Rai GS
    J Am Geriatr Soc; 2003 Apr; 51(4):572-3. PubMed ID: 12657085
    [No Abstract]   [Full Text] [Related]  

  • 44. [Angiotensin-converting enzyme inhibitors :from vasoactive drugs to cardiovascular prevention tools].
    Modesti PA; Vanni S; Gensini GF
    Ital Heart J Suppl; 2003 Aug; 4(8):623-34. PubMed ID: 14655458
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.
    Ball SG; White WB
    Am J Cardiol; 2003 May; 91(10A):15G-21G. PubMed ID: 12781904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative role of angiotensin receptor blockers versus other agents in the management of hypertension, cardiovascular disease and nephropathy.
    Tempelhof MW
    South Med J; 2009 Dec; 102(12):1201-2. PubMed ID: 20016423
    [No Abstract]   [Full Text] [Related]  

  • 48. [The use of aldosterone antagonists in the cardiovascular diseases].
    Trzaska E; Gumułka W; Makulska-Nowak HE
    Kardiol Pol; 2009 Jun; 67(6):667-71. PubMed ID: 19618325
    [No Abstract]   [Full Text] [Related]  

  • 49. Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases.
    Gerc V; Buksa M
    Med Arh; 2010; 64(5):295-9. PubMed ID: 21287956
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients.
    Costanzo P; Perrone-Filardi P; Petretta M; Marciano C; Vassallo E; Gargiulo P; Paolillo S; Petretta A; Chiariello M
    J Hypertens; 2009 Jun; 27(6):1136-51. PubMed ID: 19451836
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.
    Peters DC; Noble S; Plosker GL
    Drugs; 1998 Nov; 56(5):871-93. PubMed ID: 9829159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [ACE-inhibitors and cardiovascular protection].
    Agabiti-Rosei E; Muiesan ML
    Cardiologia; 1994 Dec; 39(12 Suppl 1):139-47. PubMed ID: 7634257
    [TBL] [Abstract][Full Text] [Related]  

  • 53. National guidelines for the management of absolute cardiovascular disease risk.
    O'Callaghan CJ; Rong P; Goh MY
    Med J Aust; 2014 May; 200(8):454, 456. PubMed ID: 24794600
    [No Abstract]   [Full Text] [Related]  

  • 54. ACE inhibition in cardiovascular disease.
    Francis GS
    N Engl J Med; 2000 Jan; 342(3):201-2. PubMed ID: 10639547
    [No Abstract]   [Full Text] [Related]  

  • 55. [The use of angiotensin-converting enzyme inhibitors in anterior infarct without congestive symptoms. The arguments pro].
    de Teresa E
    Rev Esp Cardiol; 1994 Nov; 47(11):723-8. PubMed ID: 7800901
    [No Abstract]   [Full Text] [Related]  

  • 56. [The use of angiotensin-converting enzyme inhibitors in anterior infarct without congestive symptoms. The arguments contra].
    Rodríguez Lambert JL; Moris C
    Rev Esp Cardiol; 1994 Nov; 47(11):719-22. PubMed ID: 7800900
    [No Abstract]   [Full Text] [Related]  

  • 57. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Chinese expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular diseases].
    ;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Feb; 35(2):97-106. PubMed ID: 17445398
    [No Abstract]   [Full Text] [Related]  

  • 59. Who is fooling us?
    Sleight P; Yusuf S
    Lancet; 2002 Sep; 360(9336):873-4. PubMed ID: 12243941
    [No Abstract]   [Full Text] [Related]  

  • 60. Blockade of the renin-angiotensin system.
    Cheung BM
    Hong Kong Med J; 2002 Jun; 8(3):185-91. PubMed ID: 12055364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.